N/A
Completed N=960
A Patient-centered Intervention Using Technology to Reduce Colorectal Cancer Disparities in Primary Care
Colo-rectal Cancer
Source: ClinicalTrials.gov NCT03407417 ↗
Enrolled (actual)
960
Serious AEs
0.0%
Results posted
May 2025
Primary outcomePrimary: Intention to Screen for Colorectal Cancer (CRC) — 4.33; 4.45 units on a scale
Summary
The purpose of this proposal is to test the efficacy of a patient-centered, tailored message intervention delivered via virtual technology for increasing colorectal cancer (CRC) screening within guidelines among racial/ethnic minority and rural patients. This protocol focuses on the clinical portion of grant NCI 1RCA207689-01A1
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Intention to Screen for Colorectal Cancer (CRC) |
4.33; 4.45 | — |
| SECONDARY Communication With a Provider About Colorectal Cancer (CRC) |
4.32; 4.33 | — |
Eligibility Criteria
Inclusion Criteria
- able to read English or Spanish at least at eighth-grade level
- have an email account or the ability to receive texts
- willingness to be re-contacted
- consent to MRR related to CRC screening
- not remember completing any CRC screening within recommended guidelines (i.e., <10 years for colonoscopy, <1 year for stool test).
- complete a FIT test:
- a) with a negative result only
- b) complete a FIT test with a positive result AND undergo a completion screening colonoscopy,
- Or c) complete a colonoscopy only.
Exclusion Criteria
- unable to read English at least at eighth-grade level
- doesn't have an email account or the ability to receive texts
- unwilling to be re-contacted
- Unable to consent to MRR related to CRC screening
- have not had <10 years for colonoscopy, or 1 year for stool test
Data sourced from ClinicalTrials.gov (NCT03407417). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.